A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2030

Conditions

TNBC, Triple Negative Breast Cancer

Interventions

DRUG

QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

QL1706

DRUG

Pirarubicin

pirarubicin

DRUG

Nab-paclitaxel

nab-paclitaxel

DRUG

Carboplatin (AUC 5)

carboplatin

DRUG

Cyclophosphamide

cyclophosphamide

All Listed Sponsors

collaborator

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

lead

Xijing Hospital

OTHER